Iadademstat + Atezolizumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Trial Timeline
Jan 20, 2026 → Jan 1, 2030
NCT ID
NCT07113691About Iadademstat + Atezolizumab
Iadademstat + Atezolizumab is a phase 1 stage product being developed by Oryzon Genomics for Extensive Stage Small Cell Lung Cancer (ES-SCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07113691. Target conditions include Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07113691 | Phase 1 | Recruiting |
Competing Products
20 competing products in Extensive Stage Small Cell Lung Cancer (ES-SCLC)